RGL-305+ Lymphoma + Exploratory Clinical Study

计划入组 12 人 · 首次发布于 2025 年 6 月 5 日

Survival Prolongation by Rationale Innovative Genomics

计划入组 15 人 · 首次发布于 2017 年 12 月 29 日

A Retrospective Real-World Study Based on RATIONALE-307

计划入组 109 人 · 首次发布于 2026 年 3 月 18 日

CMB-305

AP-305

Aquestive Therapeutics

United States

Oncodesign SA

France

RESOLVE THERAPEUTICS LLC

United States

European Commission Approves Tislelizumab Plus Chemotherapy for ESCC and GEJ Cancer

Tislelizumab Plus Chemotherapy Poised for EU Approval in Gastric, GEJ Adenocarcinoma, and ESCC

FDA Approves Tevimbra Plus Chemotherapy for First-Line Treatment of Gastric and GEJ Adenocarcinoma